Janney Montgomery Scott LLC Purchases Shares of 4,924 STAAR Surgical (NASDAQ:STAA)

Janney Montgomery Scott LLC purchased a new stake in shares of STAAR Surgical (NASDAQ:STAA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,924 shares of the medical instruments supplier’s stock, valued at approximately $259,000.

Other institutional investors have also added to or reduced their stakes in the company. Evermay Wealth Management LLC grew its holdings in STAAR Surgical by 100.0% during the 1st quarter. Evermay Wealth Management LLC now owns 600 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 300 shares in the last quarter. Lazard Asset Management LLC lifted its stake in shares of STAAR Surgical by 131.1% in the 1st quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 388 shares during the last quarter. UBS Group AG lifted its stake in shares of STAAR Surgical by 130.7% in the 2nd quarter. UBS Group AG now owns 805 shares of the medical instruments supplier’s stock valued at $57,000 after purchasing an additional 456 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of STAAR Surgical by 348.4% in the 2nd quarter. Captrust Financial Advisors now owns 825 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 641 shares during the last quarter. Finally, Money Concepts Capital Corp lifted its stake in shares of STAAR Surgical by 125.0% in the 4th quarter. Money Concepts Capital Corp now owns 1,251 shares of the medical instruments supplier’s stock valued at $61,000 after purchasing an additional 695 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 75,299 shares of the company’s stock in a transaction that occurred on Friday, October 6th. The shares were purchased at an average cost of $37.62 per share, for a total transaction of $2,832,748.38. Following the purchase, the insider now directly owns 9,469,723 shares in the company, valued at $356,250,979.26. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other STAAR Surgical news, Director Elizabeth Yeu Lin bought 2,500 shares of the company’s stock in a transaction that occurred on Thursday, September 21st. The shares were purchased at an average cost of $40.00 per share, for a total transaction of $100,000.00. Following the purchase, the director now directly owns 2,855 shares in the company, valued at $114,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Broadwood Partners, L.P. purchased 75,299 shares of the stock in a transaction on Friday, October 6th. The shares were purchased at an average cost of $37.62 per share, with a total value of $2,832,748.38. Following the transaction, the insider now owns 9,469,723 shares in the company, valued at approximately $356,250,979.26. The disclosure for this purchase can be found here. Insiders have acquired a total of 352,644 shares of company stock worth $13,936,203 in the last ninety days. 1.10% of the stock is owned by insiders.

STAAR Surgical Trading Up 5.0 %

Shares of NASDAQ:STAA opened at $37.81 on Friday. STAAR Surgical has a 12-month low of $34.31 and a 12-month high of $81.81. The business’s fifty day simple moving average is $41.32 and its 200-day simple moving average is $50.70. The company has a market capitalization of $1.83 billion, a PE ratio of 96.95 and a beta of 1.05.

STAAR Surgical (NASDAQ:STAA) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.04. STAAR Surgical had a return on equity of 6.43% and a net margin of 6.27%. The firm had revenue of $92.31 million for the quarter, compared to the consensus estimate of $93.04 million. Research analysts predict that STAAR Surgical will post 0.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Piper Sandler lowered their price objective on STAAR Surgical from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday. Stifel Nicolaus decreased their price target on STAAR Surgical from $45.00 to $40.00 and set a “hold” rating for the company in a research note on Friday, September 22nd. Mizuho reissued a “buy” rating and set a $65.00 price target on shares of STAAR Surgical in a research note on Wednesday, September 13th. Stephens reissued an “overweight” rating and set a $57.00 price target on shares of STAAR Surgical in a research note on Monday, August 14th. Finally, Canaccord Genuity Group lowered STAAR Surgical from a “buy” rating to a “hold” rating and decreased their price target for the stock from $77.00 to $48.00 in a research note on Thursday, August 3rd. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, STAAR Surgical has a consensus rating of “Hold” and a consensus price target of $54.33.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.